Long Term Study of Avonex Therapy Following a First Attack of Multiple Sclerosis (CHAMPIONS10)
Multiple Sclerosis, Optic Neuritis, Transverse Myelitis
About this trial
This is an interventional treatment trial for Multiple Sclerosis focused on measuring Multiple sclerosis, Interferon Beta, MRI, Optic neuritis, Transverse Myelitis
Eligibility Criteria
Inclusion Criteria: Previous participation in CHAMPS study Participation in a study site willing to participate in the CHAMPIONS10 extension study Willingness to enroll in the CHAMPIONS 10 extension Willingness to sign informed consent Exclusion Criteria: Discovery of an alternative neurological disorder other than MS as a cause of initial neurological symptoms A severe systemic disease with likely mortality within 3 years
Sites / Locations
- MS Treatment Center at Griffin Hospital
- Jaeb Center for Health Research
- MS Center of Atlanta
- Beta Research, Inc
- University of Iowa College of Medicine
- Beth Israel Deaconess Medical Center
- Michigan State University
- St. Louis University Health Sciences Center
- Jacobs Neurological Institute
- University of Rochester
- Carolinas Medical Center - MS Center
- Cleveland Clinic Foundation
- The Ohio State University
- The Neurology Group
- Univeristy of Pennsylvania Medical Center
- Allegheny Neurological Associates
- Univeristy of Texas Houston Health Science Center
- Virginia Commonwealth University/Medical College of Virginia
- Neurological Associates, Inc.
- Marshfield Clinic
- Vancouver Hospital Health Sciences Centre
- QEII Health Sciences Centre
- Ottawa General Hospital
- University of Toronto - St. Michael's Hospital
- Hospital Notre Dame
- Montreal Neurological Institute
Arms of the Study
Arm 1
Arm 2
Experimental
Active Comparator
Immediate Treatment Group
Delayed Treatment Group
Initiation of treatment with Interferon Beta 1a IM once weekly immediately after onset of a first demyelinating syndrome in high risk individuals
Delayed initiation of of Interferon beta-1a IM once weekly at diagnosis of clinically definite MS, at conclusion of initial CHAMPS study or during long term observation